SCHEMBL9434876

SCHEMBL9434876

CN(C)CCCN1CCN(CCCN(C)C)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.50
ALDH1A1 P00352 2/20 0.45
TSHR P16473 1/20 0.45
PIM1 P11309 1/20 0.45
HRH3 Q9Y5N1 2/20 0.39
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
HTR3E A5X5Y0 1/20 0.38
SLC22A2 O15244 1/20 0.38
SLC22A1 O15245 1/20 0.38
CACNA1F O60840 1/20 0.38
SLC22A3 O75751 1/20 0.38
HTR3B O95264 1/20 0.38
PRNP P04156 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
HTR1A P08908 1/20 0.38
CHRM5 P08912 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CYP2D6 P10635 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27699518 1.00
SCHEMBL7029723 0.93 ALOX15 (0.46) ALOX15ALDH1A1TSHRPIM1LMNA
SCHEMBL7644458 0.91 ALOX15 (0.45) ALOX15ALDH1A1TSHRPIM1DNM1
SCHEMBL18871718 0.91 ALOX15 (0.45) ALOX15ALDH1A1TSHRPIM1DRD2
SCHEMBL7649942 0.90 HRH3 (0.52) ALOX15ALDH1A1TSHRHRH3MAPT
SCHEMBL25106441 0.89 ALOX15 (0.56) ALOX15PIM1SMN1; SMN2
SCHEMBL18402524 0.89 ALOX15 (0.44) ALOX15ALDH1A1TSHRPIM1HRH3
SCHEMBL19524668 0.89 GNAI3 (0.53) ALOX15ALDH1A1TSHRPIM1HRH3
SCHEMBL12443471 0.89 ALOX15 (0.44) ALOX15ALDH1A1TSHRPIM1HRH3
SCHEMBL27354498 0.89 KEAP1 (0.48) ALOX15PIM1CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338411-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS RECODE THERAPEUTICS, INC. 2023-10-26 US disclosed
WO-2023141576-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS POSEIDA THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
WO-2022169508-A1 UNSATURATED DENDRIMERS COMPOSITIONS,RELATED FORMULATIONS, AND METHODS OF USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-08-11 WO disclosed
US-5283364-A Hydrolysis of isocyanates with water in presence of amide solvent BAYER AKTIENGESELLSCHAFT (DE) 1994-02-01 US disclosed
EP-0255677-B1 Process for producing Polyamino-hydroxy compounds containing urethane and/or urea groups and their use in the production of polyurea urethanes BAYER AG (DE) 1993-12-08 EP disclosed
US-4970342-A ONE STEP HYDROLYSIS OF ISOCYANATE GROUP CONTAINING COMPOUNDS IN PRESENCE OF EXCESS WATER AND TERTIARY AMINE CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1990-11-13 US disclosed
EP-0255677-A1 Process for producing Polyamino-hydroxy compounds containing urethane and/or urea groups and their use in the production of polyurea urethanes BAYER AG (DE) 1988-02-10 EP disclosed
EP-0097298-B1 POLYAMINES, PROCESS FOR PRODUCING POLYAMINES AND THEIR USE IN THE PRODUCTION OF POLYURETHANES BAYER AG (DE) 1986-04-30 EP disclosed
US-4501873-A USING BASIC CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1985-02-26 US disclosed
EP-0113020-A1 Reaction components containing amino groups, process for their preparation and their use BAYER AG (DE) 1984-07-11 EP disclosed
US-4291151-A Process for preparing polycarbonate using cyclic di- or triamine catalyst GENERAL ELECTRIC COMPANY (US) 1981-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230338411-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS CHMP4B, LIPA, NPC1L1 ALOX15 1932/4885ALDH1A1 4006/4885TSHR 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.